Press Releases
The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
23 Jul, 2024 08:30 CESTRegulatoryCyxone provides an update on its research and development program
15 Jul, 2024 08:42 CESTKjell Stenberg new CEO in Cyxone AB
22 Apr, 2024 10:02 CESTRegulatoryCyxone enters important research collaboration
25 Mar, 2024 13:44 CETCyxone reaches important milestone regarding mechanism of action
15 Jan, 2024 10:01 CET